Veymont Participations

Veymont Participations, established in 2011 by a group of 14 executives, is a growth equity firm based in Lyon, France. The firm focuses on supporting the creation, acquisition, and development of small and medium-sized enterprises by taking minority stakes in these businesses. Veymont Participations leverages the skills, experience, and networks of its associates to assist project promoters in achieving their objectives.

Gilles Balboni

Associate and Partner

Damien Bertrand

Associate and Partner

Antoine Blondel

Associate and Partner

Claude Charnay

Associate and Partner

Aymeri Chomel

Associate and Partner

Daniel Damart

Associate and Partner

Xavier Duteil

Associate and Partner

Louis Godinot

Associate and Partner

Bruno Lalo

Associate and Partner

Guillaume Mulliez

Associate and Partner

Denis Nevoret

Associate and Partner

Michel Rave

Associate and Partner

Yvan Viallon

Associate and Partner

Eric Waldner

Associate and Partner

Past deals in Lyon

TripConnexion

Seed Round in 2015
TripConnexion is an online platform that connects travelers with local experts, offering personalized travel guidance. It enables users to create tailor-made itineraries that focus on unique experiences away from typical tourist routes. By facilitating direct communication with local travel specialists, TripConnexion ensures transparency in the planning process, allowing travelers to stay informed about their trips. The platform operates without charging commissions, further enhancing its appeal to those seeking customized travel solutions. Through its services, TripConnexion aims to enrich the travel experience by providing insights and assistance from knowledgeable locals.

Calixar

Series B in 2015
Calixar provides a comprehensive range of services focused exclusively on membrane proteins (which account for over 70 per cent of therapeutic targets), including: identification, production, extraction, purification, stabilization and crystallization. Its patented technology, which has already been validated on a score of targets (including GPCR receptors, ionic channels, transporters and viral proteins), can isolate and purify any type of membrane protein in its complete native form, which remains stable in solution. The company’s services are aimed at private and public research establishments interested in the development of antibodies, especially those for therapeutic applications, drug discovery (screening and drug design) and vaccines.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.